Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period [1][2]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems [2]. - The design changes reportedly rendered the G6 and G7 devices less reliable, posing a material health risk to users [2]. - DexCom is accused of overstating the enhancements and reliability of the G7 device, downplaying the severity of issues related to adulterated devices [2]. - The company allegedly faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [2]. Group 2: Lead Plaintiff Process - Investors in DexCom can seek to be appointed as lead plaintiffs by December 26, 2025, or remain absent class members [3]. - The lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [3]. - Participation as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3]. Group 3: Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected DexCom investors to reach out for more information regarding the lawsuits [4].

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected investors between January 8, 2024, and September 17, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without approval from the U.S. Food and Drug Administration [2]. - It is alleged that these design changes compromised the reliability of the G6 and G7 devices, posing a significant health risk to users who depend on accurate glucose readings [2]. - The complaint asserts that the enhancements claimed for the G7, including its reliability, accuracy, and functionality, were overstated by the defendants [2]. - Defendants are accused of downplaying the severity of the issues and health risks associated with the altered G7 devices [2]. - The lawsuit suggests that these actions exposed DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2]. - As a result, the public statements made by the defendants were deemed materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses in DexCom, Inc. during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against DexCom, Inc. for alleged misrepresentations regarding the accuracy and functionality of its Dexcom G7 continuous glucose monitoring system, affecting investors who purchased securities between January 8, 2024, and September 17, 2025 [1][2]. Group 1 - The lawsuit claims that the defendants made false statements about the reliability and enhancements of the Dexcom G7 system, as well as the company's manufacturing capabilities [2]. - Investors who wish to serve as lead plaintiffs must file by December 26, 2025, but participation in any recovery does not require serving as lead plaintiff [3]. - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented both individual investors and large pension funds [4].

Market Overview - The US equity market experienced a rally in the third quarter of 2025, with the S&P 500 Index increasing by 8.12% [1] - Bonds also performed well, with the Bloomberg U.S. Aggregate Bond Index rising by 2.03% during the same period [1] Performance Analysis - The composite return for the quarter was 7.22% gross of fees and 7.10% net of fees, which underperformed the S&P 500 Index's gain of 8.12% [1] - The underperformance of the strategy was attributed to security selection [1] Company Spotlight: DexCom, Inc. - DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems for diabetes management and has developed innovative technology, including a small implantable device for glucose level measurement [3] - The company's products, such as the Dexcom G7 CGM system and the Stelo Glucose Biosensor, are designed for both adults and children with type 1 or type 2 diabetes, as well as adults with prediabetes and type 2 diabetes who do not use insulin [3] - As of November 13, 2025, DexCom's stock closed at $59.72 per share, with a market capitalization of $23.292 billion [2] - Over the last month, DexCom's stock experienced a return of -10.33%, and its shares lost 21.30% of their value over the past 52 weeks [2]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the upcoming lead plaintiff deadline on December 29, 2025, for a class action lawsuit related to misleading statements made by the company [1]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. - A lead plaintiff must file a motion with the Court by December 29, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 for the number of settlements in 2017 and consistently in the top 4 since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the company overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential legal repercussions [5].

Core Viewpoint - DexCom, Inc. is facing a lawsuit for alleged violations of securities laws, which may impact its financial standing and investor confidence [1] Company Summary - The lawsuit has been filed against DexCom, Inc. by the DJS Law Group, indicating potential legal challenges for the company [1] - The nature of the allegations suggests that there may be significant implications for the company's compliance with securities regulations [1] Industry Summary - The case highlights ongoing scrutiny within the healthcare technology sector, particularly regarding companies involved in diabetes management and monitoring solutions [1] - Legal actions like this can affect market perceptions and valuations of companies in the healthcare technology industry [1]

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected shareholders between January 8, 2024, and September 17, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that DexCom made false statements and concealed material design changes to its glucose monitoring products, the G6 and G7, which were unauthorized by the U.S. Food and Drug Administration [3]. - It is alleged that these design changes made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The complaint asserts that the enhancements to the G7, along with its reliability, accuracy, and functionality, were overstated, and the true scope of the issues was downplayed [3]. Group 2: Implications - The alleged actions have subjected DexCom to increased regulatory scrutiny and potential enforcement actions, leading to significant legal, reputational, and financial harm [3]. - The public statements made by the defendants are claimed to have been materially false and misleading throughout the relevant period [3]. Group 3: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 4: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing substantial recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].

Company Overview - DexCom, Inc. (DXCM) is a leading medical-device company specializing in continuous glucose monitoring (CGM) systems for diabetes management, with a market capitalization of approximately $23.2 billion [1] Stock Performance - Over the past 52 weeks, DXCM stock has declined by 19.8%, while the S&P 500 Index has increased by 14.5%. Year-to-date, the stock is down 23.4%, compared to a 16.5% rise in the S&P 500 [2] - DexCom's shares have also underperformed the Health Care Select Sector SPDR Fund, which returned 3.8% over the past 52 weeks and 11.1% year-to-date [3] Earnings and Outlook - The company reported a solid third-quarter earnings performance, beating estimates; however, management's outlook indicated that growth in 2026 may be slightly below market expectations, raising concerns among investors [4] - For the fiscal year ending December 2025, analysts project DexCom's earnings per share (EPS) to grow by 26.2% year-over-year to $2.07. The company's earnings surprise history is mixed, with two beats and two misses in the last four quarters [5] Analyst Ratings - Among 28 analysts covering DexCom, the consensus rating is a "Strong Buy," consisting of 21 "Strong Buys," one "Moderate Buy," and six "Hold" ratings [6] - The consensus rating has become slightly more bullish compared to three months ago, when there were 20 "Strong Buy" ratings [7] Price Targets - Bernstein SocGen Group recently lowered its price target for DexCom from $98 to $84 while maintaining an "Outperform" rating. The mean price target of $87.38 suggests a potential upside of 46.7% from current levels, while the highest target of $125 indicates a possible rally of 109.7% [7]

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [4]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [5]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [6]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [6]. - The allegations suggest that these misrepresentations subjected DexCom to increased regulatory scrutiny and potential legal and financial repercussions [6].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed risks related to its continuous glucose monitoring systems during the specified class period from January 8, 2024, to September 17, 2025 [1][2]. Group 1: Allegations Against DexCom - Defendants allegedly made false or misleading statements regarding unauthorized design changes to the G6 and G7 glucose monitoring systems, which compromised their reliability and posed health risks to users [2]. - The enhancements claimed for the G7 device were reportedly overstated, and the company downplayed the severity of issues related to the G7 devices [2]. - The alleged misconduct has led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [2]. Group 2: Legal Process for Investors - Investors in DexCom can seek to be appointed as lead plaintiffs by December 26, 2025, or remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select legal counsel for the case [3]. - Participation as a lead plaintiff does not affect the ability of investors to share in any recovery from the lawsuit [3].